Synbiotic Compound to Reduce Symptoms of Schizophrenia

Exclusion Criteria

• •DSM-5 diagnosis of intellectual disability or comparable diagnosis determined by previous versions of the DSM.
• •Any clinically significant or unstable medical disorder as determined by the investigators, including congestive heart failure, liver disease, renal failure, any diagnosis of cancer undergoing active treatment.
• •A primary immunodeficiency condition such as HIV infection, or undergoing cancer chemotherapy, or receiving systemic corticosteroids, methotrexate or monoclonal antibodies for treatment of an autoimmune disorder.
• •History of IV drug use.
• •DSM-5 diagnosis of a moderate or severe substance use disorder, except for caffeine or tobacco, within the last three months prior to the screening visit. If the patient has a positive drug toxicity screen at the time of visit 1 (screening) further evaluation by the investigator will be done of the substance use to determine eligibility.
• •Participated in any investigational drug trial in the past 30 days.
• •Pregnant or planning to become pregnant during the study period.
• •Receipt of antibiotic medication within the 14 days prior to visit 2 (as anaerobic organisms residing in the gastrointestinal tract may be minimally affected by antibiotics). Of note, patients on antibiotic may be re-screened once the minimum duration of time since antibiotics use has been met.
• •Current and regular use of a probiotic and or prebiotic supplement within the past 2 weeks. Of note, patients taking prebiotic or probiotic supplements may be re-screened.
• •Documented inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis) or celiac disease